Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 20/20 | 0.49 |
| ▸ | CA1 | P00915 | 8/20 | 0.41 |
| ▸ | CA12 | O43570 | 7/20 | 0.41 |
| ▸ | CA9 | Q16790 | 7/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21321761 | 0.80 | CA2 (0.43) | CA2CA1CA12CA9CA4 | |
| SCHEMBL10373558 | 0.76 | CA2 (0.45) | CA2CA1CA12CA9CA4 | |
| SCHEMBL4646901 | 0.72 | CA2 (0.43) | CA2CA1CA12CA9CA4 | |
| SCHEMBL11225579 | 0.69 | — | — | |
| SCHEMBL10372967 | 0.69 | CA2 (0.57) | CA2CA1CA12CA9CA4 | |
| SCHEMBL4702219 | 0.68 | GABBR2 (0.42) | — | |
| SCHEMBL25386903 | 0.68 | GABBR2 (0.42) | — | |
| SCHEMBL2010210 | 0.68 | CA2 (0.56) | CA2CA1CA12CA9CA4 | |
| SCHEMBL3096712 | 0.68 | CA2 (0.47) | CA2CA1CA12CA9 | |
| SCHEMBL10341109 | 0.68 | CA2 (0.47) | CA2CA1CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CA2 1245/4885CA1 3665/4885CA12 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.